chronic hepatitis C with high viral load (>
Conditions
Interventions
peginterferon alfa-2b in combination with ribavirin
peginterferon alfa-2a in combination with ribavirin
Sponsors
University of Tokyo Department of Gastroenterology, Faculty of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The study is designed to enroll patients with HCV RNA positive. 1.Chronic hepatitis C 2.HCV RNA >=100KIU/ml 3.WBC >=3000/mm3 4.Neutrophil >=1500/mm3 5.Platelet count >=90,000 6.Hemoglobin >=12g/dL 7.Patient who was explained about the study, understood it, and gave the consent form
Exclusion criteria
Exclusion criteria: The exclusion criteria are as follows: 1.liver disease such as autoimmune hepatitis, coinfection with hepatitis B, 2.severe renal disease, Ccr <50ml/min 3.poorly controlled heart disease 4.depression or psychosomatic disorders 5.Sho-saiko-to treatment within 30 days before interferon administration 6.pregnant or lactating women and women who may be pregnant 7.a man who can not avoid conception during administration of ribavirin and until 6 month after the end ribavirin treatment 8.drug allergy against interferon or ribavirin 9.allergy against biological drugs 10.no prior therapy of peginterferon in combination with ribavirin 11.on other clinical trial 12.any reason which medical doctor regard the patient as unsuitable for this test
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SVR(sustained virologic response:no detectable hepatitis C virus in their blood 6 months after treatment has ended) rate | — |
Countries
Japan
Contacts
Public ContactTadashi Goto
University of Tokyo Department of Gastroenterology, Faculty of Medicine
Outcome results
None listed